As Biotechnology businesses, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and LogicBio Therapeutics Inc. (NASDAQ:LOGC), are affected by contrast. This especially applies to their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alexion Pharmaceuticals Inc.||4.13B||7.67||77.60M||0.08||1767.27|
|LogicBio Therapeutics Inc.||N/A||0.00||17.62M||-0.66||0.00|
Demonstrates Alexion Pharmaceuticals Inc. and LogicBio Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 provides the return on assets, net margins and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Alexion Pharmaceuticals Inc.||1.88%||0.9%||0.6%|
|LogicBio Therapeutics Inc.||0.00%||0%||0%|
The Current Ratio of Alexion Pharmaceuticals Inc. is 2.9 while its Quick Ratio stands at 2.5. The Current Ratio of rival LogicBio Therapeutics Inc. is 5.7 and its Quick Ratio is has 5.7. LogicBio Therapeutics Inc. is better equipped to clear short and long-term obligations than Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc. and LogicBio Therapeutics Inc. Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Alexion Pharmaceuticals Inc.||0||1||5||2.83|
|LogicBio Therapeutics Inc.||0||0||0||0.00|
Alexion Pharmaceuticals Inc.’s upside potential currently stands at 18.66% and an $167.67 consensus price target.
Insider and Institutional Ownership
Alexion Pharmaceuticals Inc. and LogicBio Therapeutics Inc. has shares held by institutional investors as follows: 96.9% and 65.1%. Insiders held roughly 0.1% of Alexion Pharmaceuticals Inc.’s shares. Insiders Competitively, held 5.6% of LogicBio Therapeutics Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Alexion Pharmaceuticals Inc.||2.19%||10.67%||10.78%||10.81%||18.22%||39.77%|
|LogicBio Therapeutics Inc.||-3.04%||8.26%||-31.05%||0%||0%||-7.98%|
For the past year Alexion Pharmaceuticals Inc. has 39.77% stronger performance while LogicBio Therapeutics Inc. has -7.98% weaker performance.
On 10 of the 11 factors Alexion Pharmaceuticals Inc. beats LogicBio Therapeutics Inc.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. has a partnership with Children's Medical Research Institute (CMRI) of Australia to develop new viral vectors. The company was founded in 2014 and is based in Cambridge, Massachusetts.